Morphic Holding

General Information


We are a biopharmaceutical company applying our proprietary insights into integrins to discover and develop a pipeline of potentially first-in-class oral small-molecule integrin therapeutics. Integrins are a target class with multiple approved injectable blockbuster drugs for the treatment of serious chronic diseases, including autoimmune, cardiovascular and metabolic diseases, fibrosis and cancer. To date, no oral small-molecule integrin therapies have been approved by the U.S. Food and Drug Administration, or FDA. Despite significant unsuccessful efforts, we believe tremendous untapped potential remains for us to develop oral integrin therapies.

Employees: 65
Founded: 2014
Contact Information
Address 35 Gatehouse Drive, A2, Waltham, MA 02451, US
Phone Number (781) 996-0955
Web Address
View Prospectus: Morphic Holding
Financial Information
Market Cap $443.9mil
Revenues $9.4 mil (last 12 months)
Net Income $-23.9 mil (last 12 months)
IPO Profile
Symbol MORF
Exchange NASDAQ
Shares (millions): 6.0
Price range $15.00 - $15.00
Est. $ Volume $90.0 mil
Manager / Joint Managers Jefferies/ Cowen and Company/ BMO Capital Markets/ Wells Fargo Securities
CO-Managers -
Expected To Trade: 6/27/2019
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change